Related Experiment Video
Updated: Jan 14, 2026
Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
Published on: January 22, 2011
Patient perspectives on access to oncology innovations: protocol for a systematic meta-aggregation review
Allan Julliot-Delval1,2, Maria Teixeira3,2, Emmanuelle Cartron3,2,4
1SIRIC InSiTu, INSERM, Paris, France allan.julliot-delval@u-paris.fr.
Introduction:
Healthcare innovation in oncology has accelerated in recent years, with the development of targeted therapies, digital tools and novel care pathways. While these advances promise improved outcomes, concerns remain about unequal access across patient populations. Patient perspectives on access to innovation remain underexplored, yet may offer valuable insights to support more equitable and patient-centred implementation strategies.
Objectives:
This meta-aggregation study aims to explore how adult patients with cancer perceive their access to healthcare innovations. A secondary objective is to identify the barriers, facilitators and contextual factors that influence this access, as well as patients' understandings or definitions of innovation, when available.
Method And Analysis:
A systematic meta-aggregation review will be conducted according to the Joanna Briggs Institute (JBI) methodology. Full-text, peer-reviewed articles reporting qualitative studies of patients' experiences with innovations in oncology will be included. Studies will be identified through searches in PubMed, CINAHL, PsycINFO and Cairn.info, with no date restrictions. Articles in English and French will be considered. Two independent reviewers will screen and extract data and assess methodological quality using the JBI checklist. Synthesis will follow the JBI three-phase approach. Confidence in the evidence will be assessed using the GRADE-CERQual (Confidence in the Evidence from Reviews of Qualitative research) tool. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 reporting guidelines will be followed.
Ethics And Dissemination:
Ethical approval is not required for this study, as it is based on previously published data. The findings will be disseminated through publication in peer-reviewed journals and presentations at scientific conferences.
Prospero Registration Number:
CRD420251046315.
Related Concept Videos
01:27Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
01:21Cancer Survival Analysis
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...